Songzhu (Michael) An, Ph.D., is President of StemRD, a bay area biotech company specialized in stem cell reagents. Prior to founding StemRD, he was a project leader at Amgen - San Francisco where he led drug discovery projects. He has been a resident of the bay area since 1992 when he started his postdoctoral fellowship at UCSF where he spent 4 years on the faculty before joining Amgen in 2000.

Kenneth Fong, Ph.D., is the Chairman of Kenson Ventures, LLC. Kenson specializes in venture financing and strategic consulting to biotech companies. As of January 2003, Kenson has 18 investments that mostly fall into 3 major categories: a) Innovative Research Tools, b) Platform Technologies, and c) Drug Development. Prior to founding Kenson, Dr. Fong was the founder and CEO of CLONTECH Laboratories that was acquired by Becton Dickinson (BD) in late 1999. CLONTECH was the leader in the Molecular/Cell Biology market and in the last 4 years before its acquisition, the company had experienced an average growth rate of 36% a year. The company also had 48 consecutive quarters of double-digit growth and profits. In 1994, 1995, 1998, and 1999, CLONTECH was selected as one of the fastest-growing companies in the San Francisco Bay Area. Dr. Fong's past experience is best suited to young companies and to those that desire to grow more rapidly. He is also adept at crafting development strategy and realistic implementation plans to promote the long-term growth of a company. Under Dr. Fong's leadership, companies that either were acquired or went public between 2007 and 2010 are: SA Biosciences (to Qiagen); DHI (to Quidel); Fermentas (to ThermoFisher); Panomics (to Affymetrix); Bioform (IPO); and Optimer (IPO). Dr. Fong obtained his Ph.D. from Indiana University.

Ying Gong, Ph.D., received her PhD in Biochemistry and Molecular Biophysics from Caltech, studying the molecular mechanisms of vertebrate morphogenesis using zebrafish as a model. Upon graduation, she joined the management consulting firm Bain & Company, where she worked on a broad range of business strategy and operations projects in different industries. Dr. Gong joined Genentech in late 2007, where she has been responsible for commercial strategies of R&D programs in a number of therapeutic areas. Recently, she moved to a new position within Genentech and is responsible for developing reimbursement strategies.

Mougang Hu, Ph.D., is current Associate Director of analytical development and CMC at InterMune. He actively participated in NDA and MAA submission of InterMune's commercial product, Esbriet, leading all activities on analytical data and quality control in CMC section. Prior to InterMune, he worked with Patheon (CRO) where he led a team and was responsible for analytical development and project management of 10 projects at different development stages from both big pharma and biotech companies. Three of drug candidates were eventually received NDA or/and MAA approval. Dr. Hu also worked with Apotex Inc for two years and with Merck KGAA for three years. Dr. Hu holds a Ph.D. in synthetic chemistry from York University in Canada. He did postdoctoral research in McMaster University of Canada.

Tao Huang, Ph.D., J.D., currently is an attorney of Wilson Sonsini, a Silicon Valley law firm. Tao advises companies and investors in biotechnology, pharmaceutical, and nanotech industries on patent law, licensing, and business transactions. His practice specifically focuses on patent prosecution and portfolio management, patent strategy and counseling (landscaping, freedom-to-operate, invalidity and noninfringement), licensing, and investment diligence related to VC financing, M&A, and IPO. Dr. Huang graduated from Nankai University (B.S. Biophysics), Peking Union Medical College (Ph.D. in Biochemistry) and the University of Michigan Law School (J.D.). Prior to his legal career, Tao was a post-doctoral scientist at Princeton University. He has co-authored more than 20 scientific research papers and reviews, and is a member of BayHelix and a Lifetime Member of Chinese-American BioPharmaceutical Society (CABS).

Wei Huang, M.S., has responsibility for process development, engineering, and scale up at LS9. Ms. Huang brings over 20 years of industrial bioprocess experience, including research and process development, process scale up, facility and equipment design and construction, facility start-up and operation. Prior to joining LS9, Ms. Huang was Director of Process Engineering at Fluor Corporation, one of the world's largest, publicly owned engineering companies. During her tenure there, Ms. Huang successfully led various engineering projects for the biotechnology industry worldwide. Prior to joining Fluor, she worked at Bechtel, North American Vaccine (now part of Baxter) and New Brunswick Scientific Inc, where she was directly involved in the research and process development, scale up and product commercialization for both biopharmaceuticals and industrial fermentation products. Active in a variety of professional organizations such as SIM, AIChE and ISPE, Ms. Huang

serves as a committee member of ASME BPE. She is a well published author, a frequent speaker at various biotechnology events and a recipient of the ISPE Best Article of the Year award. Ms. Huang received her M.S. in Chemical Engineering from the University of Maryland specializing in biochemical engineering.

Ruhong Jiang, Ph.D., is cofounder and CEO of Applied StemCell, Inc. located in San Francisco Bay area, chairman and CEO of Stanford Biotech, Inc. at China Medical City, Taizhou, Jiangsu Province in China. He has held a variety of technical and managerial roles with increasing responsibilities in several biotechnology/biopharmaceutical companies. Before starting Applied StemCell, Ruhong was general manager of MicuRx (Shanghai) Pharmaceutical, Inc. a California-based biopharmaceutical company where he set up its entire China operation. From 2005-2007, Dr. Jaing was head of the Pharmacogenetics Program at Stanford Research Institute International (SRI) where he managed multiple pharmacogenetic and molecular genetics projects with multi-millions of annual budget. Prior to relocating to California, Dr. Jiang was pharmacogenomics consultant at Boehringer Ingelheim Pharmaceuticals and served as senior scientist, then project manager at Genaissance Pharmaceuticals from 2000-2004 where he played an important role in biomarker discovery, pharmacogenetics and clinical bioinformatics, diagnostic product development, alliance management and business development. Dr. Jiang graduated from Fudan University with a B.S. degree in biology, and received M.S. degree in reproductive biology from China Agricultural University and a Ph.D. degree in Genetics from Oklahoma State University in 1997. From there Ruhong went to Baylor College of Medicine where he furthered his education as a postdoctoral fellow in Dr. Douglas Burrin's lab. Dr. Jiang has authored and co-authored more than 40 publications in the fields of human genetics, pharmacogenetics and disease animal models. Ruhong has a deep interest in the science, ethics and societal issues of personalized medicine, regenerative medicine and global health. His demonstrated leadership has led to an established track record of success; especially in the areas of biomarker-based molecular assays or diagnosis, CRO service, and drug research and development.

Cheni Kwok, Ph.D., CLPTM, Senior Vice President, Corporate Development, joined Poniard Pharmaceuticals in July 2006 as the Vice President of Business Development. She established corporate and business development, strategic and commercial planning, new product planning, competitive intelligence and forecasting functions at Poniard. Previously, Dr. Kwok was Director of Business Development at Celera Genomics from 2004 to 2006, where she led the business development efforts for Celera's small molecule therapeutics programs. Prior to Celera, Dr. Kwok held business development positions of increasing responsibility for Exelixis Inc. from 2000 to 2004, where she initiated multiple partnerships and served as the alliance manager for the GlaxoSmithKline collaboration. Prior to joining Exelixis Inc., Dr. Kwok held various research management, technology assessment and alliance management roles at SmithKline Beecham Pharmaceuticals from 1997 to 2000. She received a bachelor's degree in biotechnology from Imperial College of Science, Technology and Medicine, University of London, UK and a Ph.D. in human molecular genetics from the University of Cambridge, UK. Dr. Kwok obtained the Certified Licensing Professional (CLPTM) credential established by the Licensing Executive Society (USA and Canada).

Leping Li, Ph.D., serves as the Vice President of Chemistry at Presidio Pharmaceuticals, Inc. a San Francisco-based biopharmaceutical company. Prior to joining Presidio in 2007, Dr. Li held various scientific management positions at Amgen (and formerly Tularik), most recently as a Scientific Director in medicinal chemistry. Dr. Li's professional career also includes a 7-year stay at Abbott Laboratories during the late 1990s. Dr Li was trained as an organic chemist with a Ph.D. degree from Rice University and a postdoctoral fellowship at Stanford University. He graduated from Shandong University in 1983; the following year he came to the USA on an exchange fellowship (CGP). In his nearly 20 years' professional career both with large and small companies, he has been involved in drug discovery programs from early lead identification to advanced clinical development stages across several therapeutic areas, including infectious diseases, cancers and metabolic disorders.

Charlene Liao, Ph.D., holds Ph.D. in Biology from Brandeis University and a B.S. in Biochemistry from Peking University. She conducted postdoctoral research in immunology and signal transduction at UCSF where she was a Fellow of the Damon Runyon Cancer Research Fund and a Special Fellow of the Leukemia and Lymphoma Society of America. Dr. Liao began her bio-pharmaceutical industry career at Tularik Inc. (now Amgen) as a Scientist. Prior to joining Genentech Dr. Liao held various leadership positions at Rigel Inc., including Project Leader, Associate Director, and Director of Business Development. Dr. Liao joined Genentech in 2002 and has been a Project Team Leader since 2007. She has contributed to IND filing for 8 NMEs

including large and small molecule drugs and across the therapeutic areas of oncology, immunology and infectious diseases. Dr. Liao is one of the founding members and Board of Directors of the Ray Wu Memorial Fund.

Zheng (Jen) Liu, J.D., Her practice focuses on patent and trade secrets litigation, intellectual property counseling, due diligence and technology transactions across a broad range of industries, including biotechnology, pharmaceutical, medical devices, Internet and telecommunications. She has been lead associate for many patent infringement and commercial litigation cases and has argued important issues such as claim construction in front of federal court judges and examined witnesses in front of juries. She also advises Chinese companies on a wide range of legal issues specific to Chinese companies doing business in the United States or with foreign companies, including intellectual property, commercial disputes, corporate, real estate, investments, etc. Prior to Orrick, Ms. Liu was with a prominent IP litigation boutique firm and Johnson & Johnson. She has a J.D. from UC Berkeley School of Law, a M.S. from Ohio State University and she is an alumnus of the University of Science & Technology of China (ZhongKeDa).

Cheng Liu, Ph.D., is the founder and CEO of Eureka Therapeutics, a California biotech company dedicated to antibody research and discovery for next-generation cancer therapeutics. Prior to founding Eureka, Dr. Liu was a Principal Scientist in Antibody Drug Discovery at Chiron Corporation (now part of Novartis), where he championed the anti-CSF1 antibody program for treatment of bone metastasis. The program is currently in human clinical trials. Dr. Liu is the lead inventor of more than ten drug discovery patents filed in the US and Europe. In 2007, he was awarded Special Congressional Recognition for his contributions to improving human health. Dr. Liu received his B.S. in Cell Biology and Genetics from Beijing University and a Ph.D. in Molecular Cell Biology from the University of California, Berkeley.

Andrew Luk, Ph.D., has over 12 years of experience focused in the areas of sustained drug release and drug-device combination products. He has led teams in advancing product concepts, spanning devices for systemic delivery as well as drug-eluting devices for local delivery, from feasibility assessment to full development. Andrew is currently leading a New Technologies team at CooperVision. Prior to CooperVision, Andrew was with Johnson & Johnson (via acquisition of ALZA and Conor MedSystems) responsible for all aspects of CMC development of protein delivery systems and drug-eluting stents, with an active role in preparation of IND, IDE, and PMA submissions.

John Mao, Ph.D., is currently the Senior Vice President and Head of Development at Foresee Pharmaceuticals, LLC. Prior to Foresee, he was the Vice President of Nonclinical Development at Cytokinetics, Inc., Executive Director of Pharmaceutical Development and Analytical Pharmacology at Praecis Pharmaceuticals, and Senior Director of Analytical/DMPK at Idenix Pharmaceuticals. With over 20 years of experience in the pharmaceutical/biotechnology industry, Dr. Mao has broad expertise in preclinical and clinical development of novel therapeutics in multiple therapeutic areas such as antiviral, oncology, cardiovascular, autoimmune, and neuromuscular diseases. He has a proven track record of successful management and execution of large CMC and preclinical development programs from lead optimization to IND enabling to Phase I – III clinical development, and was actively involved in the filing of more than 10 INDs and 2 NDAs. Dr. Mao received a BS in Chemistry from Fudan University in 1985, and a MS and a Ph.D. in Analytical/bioanalytical Chemistry from University of Rhode Island in 1988 and 1994, respectively.

Shichang Miao, Ph.D., is a past president of CABS (2009-2010). He is employed as Senior Director, Discovery & Clinical Drug Metabolism / Pharmacokinetics at ChemoCentryx Inc., a public biotech company focusing on the drug discovery and development through regulation of chemokine receptors. Previously, he was a director in the pharmacokinetics and drug metabolism department at Amgen South San Francisco. He worked at Tularik Inc. from 1994 through 2004 (most recently as Associate Director, Analytical Chemistry and Drug Metabolism) until Tularik's acquisition by Amgen. He holds a Ph.D. in organic chemistry / natural products chemistry from the University of British Columbia (Vancouver) and carried out postdoctoral research in organic chemistry and biochemistry. In addition to his CABS leadership activities, he is also the founder and president of CACO Pharmaceutical & BioScience Society (CACO-PBS), a professional organization of 3000+ members with chapters in the San Francisco Bay Area and San Diego.

Zhonghua Pei, Ph.D., is currently a senior scientist and project leader at Genentech, Inc. His current role is leading a highly talented multi-disciplinary team to discovery novel drugs to treat inflammatory diseases. In the past, Zhonghua has led or

worked on projects for treating cancer and metabolic diseases. He is a major contributor to several drug development candidates which have entered human clinical trials. Zhonghua has been an executive member of CABS since 2009 and was the Co-chair of Business & Career committee which organized the CAN program of 2011. Zhonghua has enjoyed being a mentor in CAN 2011.

Zhenhai Shen, Ph.D., is current Global Category Head for Research Services at Genentech/Roche responsible for research outsourcing activities for both Genentech and Roche. He received his Ph.D. Degree from The Mount Sinai School of Medicine and completed his postdoctoral training at Dana-Farber Cancer Institute. Zhenhai also holds a MBA degree from Ross School of Business of University of Michigan. Prior to Genentech, Zhenhai worked in Eli Lilly's International Finance group.

Yongming (Andrew) Sun, Ph.D., is Sr Staff Bioinformatics Scientist at Ion Torrent, part of Life Technologies. Ion Torrent is a pioneer in using semiconductor technology in DNA sequencing. He is working in the development of sequencing applications, working with collaborators in applying Ion Torrent sequencing technologies. Prior to Ion Torrent, he worked in Life Technologies for 6 years in the area of microarray and next-generation sequencing where he participated in international projects (such MAQC microarray, 1000 Genomes Project), and led a group in working with next-generation sequencing customers in data analysis, bioinformatics workflow, and data interpretation. Prior to Life Technologies, he led bioinformatics effort in biomarker identification at diaDexus, a joint venture between Glaxo-SmithKline and Incyte. He has BS in Zoology from Nanjing University, and Ph.D. in Medical and Molecular Genetics from Indiana University. He is a co-inventor of over 20 patents.

Hong Tan, Ph.D., is the founder CEO of ET Healthcare, focused on innovative bioanalytical and diagnostics technologies. In early 2000, Hong founded Wave Crossing Corporation in the US, and served as CEO and President. He established its wholly owned Chinese subsidiary where a new type of GRIN lens (a key fiber optic component) was successfully developed. Wave Crossing was later renamed Global Optron and became a leading supplier of GRIN lenses for the fiber optic communications industry. In late 2001, Hong founded ForteBio, Inc. in Silicon Valley and bootstrapped the company in China. He created the Octet product concept, the world's first volume-manufactured fiber optic biosensor. He established and managed ForteBio's Shanghai subsidiary where millions of advanced biosensors and key instrument components have been produced. ForteBio is now a market leader in label-free analysis, and was acquired by Pall, Inc in December 2011.Prior to his entrepreneurial career, Hong designed disk drive servo control systems at Iomega, Maxtor, Seagate, Conner Tech, and Caleb Tech. He was a key member to develop the highly successful Zip and Jaz removable disk drives that enabled Iomega to achieve 0 to $1 billion revenue ramp within a year. His experience also includes developing the tracking control system for a NASA space telescope that was launched in 1993. He holds PhD and MSEE from Auburn University in the US, BSEE from Xi'an Jiao Tong University in China, and EMBA degree from Cheung Kong Graduate School of Business in Beijing, China.

Yingfei Wei, Ph.D., joined 3SBio in August 2006. She has over fifteen years of research and development experience in the biotechnology and pharmaceutical sectors. Before joining 3SBio, Dr. Wei was the Co-founder, President and Chief Executive Officer of Elixirin Corporation from 2004 to 2005, responsible for overseeing contract research, manufacturing, regulatory approvals and marketing of anti-aging products in the U.S. and China. Prior to that, she was Director of Biotechnology Research at Bayer HealthCare Global from 1998 to 2004 and group leader at the discovery research department of Human Genome Sciences Inc. from 1993 to 1998. Dr. Wei is the inventor of 37 patents and has authored several publications, primarily in the areas of protein and antibody drug discovery and genomics. Dr. Wei was a postdoctoral fellow at Harvard University's School of Public Health in 1993. She received her Ph.D. in biochemistry from the University of California in 1990 and a bachelor's degree in biochemistry from Beijing University in 1983.

Janet (Jian) Xiao, Ph.D., J.D., is a partner in Morrison & Foerster's Life Science Group residing in the Palo Alto office. She primarily represents clients in the biotechnology and pharmaceutical industries in their world-wide patent procurement, patent portfolio management, and strategic planning. Dr. Xiao has significant experience in developing and strengthening her clients' complex patent portfolios to maximize their commercial value and success. She advises biopharmaceutical companies such as Celgene and Genentech and research institutions such as University of California on patent matters relating to various technologies including antibody therapeutics, personalized medicine, drug delivery systems, drug

screening platforms, diagnostics, and nutraceuticals. She also represents many start-up biopharmaceutical companies to help them build a strong IP position from the inception. She also prepares legal opinions on patent validity and freedom to operate, conducts IP due diligence reviews for business transactions, and is among the very few IP attorneys who are both equipped with solid skills in global strategic IP management and knowledgeable about IP issue unique to China. She is frequently called upon to advise clients on IP issues relating to US/China cross-border transactions and operations in China, and is frequently invited to speak on IP issues both in the US and in China.

Shouhua (Josh) Xiao, Ph.D., has worked in the biotech industry for more than a decade. He has recently jumped into the entrepreneurship. Before that, he was most recently Principal Scientist, Oncology Research atAmgen, Inc, lead the antibody drug discovery efforts for Oncology at Amgen South San Francisco. Prior to that, he was Principal Scientist in the Lead Discovery Department, lead the assay development/HTS/molecular pharmacology group at the same Amgen site. Josh joined Amgen in 2004 via Amgen'sacquisition of Tularik, where he worked in a similar role since 2003. Prior to Tularik, he had worked at Millennium Pharmaceuticals for five years, also in Lead Discovery, where he established a very successful HTS-compatible substrate ID platform for novel targets including protein kinases and other transferases from functional genomics efforts. Dr. Xiao obtained his Ph.D. degree in Biochemistry from Louisiana State University and conducted his postdoctoral training with Dr. James Manley at Columbia University, New York. He has served as Co-chair of the CABS EC Science committee 2010-2011, and is currently Co-chair of CABS EC Business & Career Development Committee, leading the CABS Entrepreneurs Club. Josh enjoys outdoor activities, such as bicycling, skiing, and hiking.

Jinfu Yang, Ph.D., has over 15 years of industry experience in drug discovery and development. He has served as Director of Drug Metabolism and Pharmacokinetics (DMPK) and core team member at Calithera Biosciences since the company's founding in June 2010. Prior to joining Calithera, Dr. Yang worked at biotech companies including Proteolix, Cytokinetics and Ocean Pharmaceuticals and served as Associate Director, Senior Scientist and Scientist. Jinfu Yang received his B.S. from Zhejiang University of Technology, China and Ph.D. degree from Changchun Institute of Applied Chemistry, Chinese Academy of Sciences; and completed post-doctoral fellowship at University Of Dortmund, Germany.

Guo-Liang Yu, Ph.D., is Chairman, President and CEO, Epitomics Inc., an emerging biotech company with 230 employees dedicated to the development of innovative monoclonal antibodies for discovery, diagnostics and therapeutics. Epitomic is headquartered in the San Francisco Bay Area and has a wholly owned subsidiary in Hangzhou, China. Guo-Liang was Senior Vice-President of Research and Development at Mendel Biotechnology Inc. where his team analyzed the function of a complete set of plant transcription factors by knock-out and over-expression in planta. Guo-Liang was a Senior Scientist at Human Genome Sciences Inc. where he discovered the target Blys for the lupus drug belimumab. Guo-Liang was trained at Harvard Medical School as a postdoctoral fellow and earned a Ph.D. degree with Nobel Laureate Dr. Elizabeth Blackburn in Molecular Biology from the University of California, Berkeley and B.S. degree in Biochemistry from Fudan University in Shanghai. Guo-Liang is a co-inventor of more than 130 patents and a co-author of 37 scientific articles. Guo-Liang is the founding president of Chinese Biopharmaceutical Association and service on several professional organizations in the US and China as a member of the board of directors or board of advisory.

Jack Zhai, Ph.D., also known by his Chinese name of Zhai Ye, was among the first 100 outstanding talents selected by the Chinese government in 1987 to qualify for fully financially-funded overseas graduate studies. Before pursuing his PhD in Cell and Molecular Biology at the University of Wisconsin-Madison in 1987, Jack received his MS degree in Biophysics at the Chinese Academy of Agriculture Sciences and also received comprehensive training in fine instrumentation at Qinhua University, one of the most prestigious Universities in the world. In 1993, Jack received his PhD at the University of Wisconsin-Madison and completed his Hooper Foundation Postdoctoral Fellowship at the University of California, San Francisco. He nearly completed (MBA) business training at the Haas School of Business, UC Berkeley. Jack has more than 20 years experience within the life sciences industry, having expertise in the areas of cell biology, cancer biology, and genomics. Jack has published a number of important research papers regarding cell division and mitosis in peer-reviewed journals such as "Journal of Cell Biology". His two important discovery publications about microtubule dynamics during mitosis have been incorporated into today's "Cell Biology" text book edited by Bruce Alberts, and Dr. Zhai has important technology patents with the University of California San Francisco. Jack Zhai also has 15 years of experience working for Fortune 500 companies

including Applied Biosystems, Invitrogen, and Millipore including roles involving technology commercialization, product management, strategic marketing and sales, and technology licensing. Currently, Jack serves as the Vice President of Sales and Marketing at AllCells, LLC, a leading global provider of human primary cells and related services for the life science industry, based in the San Francisco Bay Area. Jack is recognized as a biotechnology authority in the Asia Pacific region and has been invited by the Chinese government and Hong Kong to give speeches on the state of the Chinese biotech business. Besides Jack's tenure in the life sciences industry, since 2000 he has served as a Biotech Business Consultant for the Chinese International Talent Development Center at the Foreign Liaison Department, an adjunct professor at Shanghai Institute of Microsystems, Chinese Academy of Sciences, and an adjunct professor at Business School of Northwest University at Xi'an.

Jimmy Zhang, Ph.D., MBA, is a Senior Vice President at Synergenics, LLC, a professional service and investment company founded and led by Dr. Bill Rutter, one of the founding fathers and pioneers of the biotech industry. Synergenics-invested companies cover areas such as therapeutic human monoclonal antibodies, gene therapy, cancer genomics, diabetes, diagnostics, healthcare IT, nutriceutical, vaccine, and biological manufacturing. Dr. Zhang is responsible for the business development of Synergenics and its portfolio companies, and their businesses in China. In addition, Dr. Zhang represented a U.S. public company and led the negotiation of a biotech incubator and industrial real estate investment in a top 3 China city, amounting to $100M. Dr. Zhang was previously a consultant at McKinsey & Company traveling and working in China, US and Germany. He worked on a wide range of issues and challenges faced by different industries (for example, pharmaceutical, chemicals, steel, investment funds, consumer, energy, government) encompassing, for example, strategic planning, global and country strategies, market entry and expansion strategies, M&A/business development, operations, organizations, marketing etc. Before pursuing his MBA degree at MIT Sloan School of Management, Dr. Zhang was a registered patent agent in the Palo Alto office of Morrison & Foerster. Dr. Zhang managed intellectual property portfolios for healthcare clients, including one exceeding US$1 billion in value, drafted and negotiated patent applications with U.S. Patent Office, and participated in patent litigations. Prior to Morrison & Foerster, Dr. Zhang served as a project manager at Chiron Corporation (now part of Novartis). Dr. Zhang received his B.S. in biochemistry from Nanjing University, and Ph.D. in biomedical sciences from the University of Texas Southwestern Medical Center at Dallas. While studying his MBA in MIT Sloan, he was a finalist of the 12th Annual MIT $50K Entrepreneurship Competition. Dr. Zhang published in Cell, Nature, Neuron, and JBC, and holds multiple patents. He's a founding member and a Board Director of BayHelix Group, a prestigious non-profit organization of Chinese life sciences business leaders. Dr. Zhang is also the Strategic Advisor to both ChinaSF and China Committee of Bay Area Council.

Tony (Dongxiao) Zhang, Ph.D., is the co-founder, President and CEO of Formurex, Inc., a pharmaceutical CRO in Stockton, CA. He is also an adjunct professor in the Department of Pharmaceutics and Medicinal Chemistry at University of the Pacific in Stockton, California. Prior to co-founding Formurex, Dr. Zhang was the co-founder and vice president of Epitomics, Inc., a leading antibody company in Burlingame, California. At Epitomics, Dr. Zhang led the technology development and was awarded by the U.S. government with multiple SBIR grants (Phase I and II). Prior to his Epitomics venture, Dr. Zhang was a senior research scientist at Bayer Corporation. At Bayer, Dr. Zhang headed a high throughput screening (HTS) group to screen for novel drug leads and to discover antibody targets for cancer therapeutics. Dr. Zhang obtained his Ph.D. in Biochemistry at Case Western Reserve University and did his postdoctoral research at Genentech, where he developed genomic technologies and discovered novel drug targets. He received his MBA degree from St. Mary's College in California. He is a member of several Chinese-American associations including BayHelix, CABS, and CBA.

Jenny Zhong, Ph.D., is Associate Director, Group Leader of Regulatory Project Management Group in Genentec/Roche PD (Product Development) Regulatory. Jenny joined PDR in September 2011 taking the responsibility to build project management capacity to support global filings across all TAs in PDR. Prior to joining PDR, Jenny was a Senior Global Project Manager with PDPP and legacy Genentech DPM organization. During her six-and-a-half years with Genentech/Roche, Jenny has served as GPM on many projects, including Zelboraf LCT and GDT, Avastin BC/GYN/MM DST, etc. and supported 3 INDs, 3 sBLAs and 3 ODACs. Prior to joining Genentech, Jenny worked at Applera as Program Manager and launched 4 genomic products on TaqMan Gene Expression and Genotyping Assays. Jenny received her training in Molecular Biology and started her career in Biotech as scientist.